Tong Ren Tang Registers Danggui Buxue Granules in Hong Kong
Beijing Tong Ren Tang Group (SHA:600085) received the certificate of registration from Hong Kong's Chinese Medicine Council for Danggui Buxue granules, according to the company's filing on the Shangha
Huluwa Pharmaceutical Gets Nod to Register Two Drugs
Hainan Huluwa Pharmaceutical Group (SHA:605199) obtained a drug registration certificate from China's National Medical Products Administration for bromhexine hydrochloride injection and desloratadine
GuangYuYuan Chinese Herbal Medicine Co., Ltd.'s (SHSE:600771) Business Is Yet to Catch Up With Its Share Price
When you see that almost half of the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 3.4x, GuangYuYuan Chinese Herbal Medicine Co., Ltd. (SHSE:600771) lo
Investors Still Aren't Entirely Convinced By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) Earnings Despite 25% Price Jump
Despite an already strong run, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) shares have been powering on, with a gain of 25% in the last thirty days. Unfortunately, th
Does Beijing Tongrentang (SHSE:600085) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortun
Da Ren Tang (600329): Outstanding industrial performance, smooth mixed improvement exhibition
Key investment events: Daren Tang released its 2024 quarterly report. During the reporting period, it achieved revenue of 2,086 billion yuan (-3.19% YoY), net profit attributable to mother of 387 million yuan (YoY -3.36%), deducting net profit from non-return to mother3